{"pre_text": ["table of contents hologic , inc .", "notes to consolidated financial statements ( continued ) ( in thousands , except per share data ) the acquisition also provides for up to two annual earn-out payments not to exceed $ 15000 in the aggregate based on biolucent 2019s achievement of certain revenue targets .", "the company considered the provision of eitf 95-8 , and concluded that this contingent consideration represents additional purchase price .", "as a result , goodwill will be increased by the amount of the additional consideration , if any , as it is earned .", "as of september 26 , 2009 , the company has not recorded any amounts for these potential earn-outs .", "the allocation of the purchase price was based upon estimates of the fair value of assets acquired and liabilities assumed as of september 18 , 2007 .", "the components and allocation of the purchase price consisted of the following approximate amounts: ."], "post_text": ["as part of the purchase price allocation , all intangible assets that were a part of the acquisition were identified and valued .", "it was determined that only customer relationship , trade name and developed technology had separately identifiable values .", "the fair value of these intangible assets was determined through the application of the income approach .", "customer relationship represented a large customer base that was expected to purchase the disposable mammopad product on a regular basis .", "trade name represented the biolucent product name that the company intended to continue to use .", "developed technology represented currently marketable purchased products that the company continues to sell as well as utilize to enhance and incorporate into the company 2019s existing products .", "the deferred income tax liability relates to the tax effect of acquired identifiable intangible assets and fair value adjustments to acquired inventory , as such amounts are not deductible for tax purposes , partially offset by acquired net operating loss carryforwards of approximately $ 2400 .", "4 .", "sale of gestiva on january 16 , 2008 , the company entered into a definitive agreement pursuant to which it agreed to sell full u.s .", "and world-wide rights to gestiva to k-v pharmaceutical company upon approval of the pending gestiva new drug application ( the 201cgestiva nda 201d ) by the fda for a purchase price of $ 82000 .", "the company received $ 9500 of the purchase price in fiscal 2008 , and the balance is due upon final approval of the gestiva nda by the fda on or before february 19 , 2010 and the production of a quantity of gestiva suitable to enable the commercial launch of the product .", "either party has the right to terminate the agreement if fda approval is not obtained by february 19 , 2010 .", "the company agreed to continue its efforts to obtain fda approval of the nda for gestiva as part of this arrangement .", "all costs incurred in these efforts will be reimbursed by k-v pharmaceutical and are being recorded as a credit against research and development expenses .", "during fiscal 2009 and 2008 , these reimbursed costs were not material .", "the company recorded the $ 9500 as a deferred gain within current liabilities in the consolidated balance sheet .", "the company expects that the gain will be recognized upon the closing of the transaction following final fda approval of the gestiva nda or if the agreement is terminated .", "the company cannot assure that it will be able to obtain the requisite fda approval , that the transaction will be completed or that it will receive the balance of the purchase price .", "moreover , if k-v pharmaceutical terminates the agreement as a result of a breach by the company of a material representation , warranty , covenant or agreement , the company will be required to return the funds previously received as well as expenses reimbursed by k-v .", "source : hologic inc , 10-k , november 24 , 2009 powered by morningstar ae document research 2120 the information contained herein may not be copied , adapted or distributed and is not warranted to be accurate , complete or timely .", "the user assumes all risks for any damages or losses arising from any use of this information , except to the extent such damages or losses cannot be limited or excluded by applicable law .", "past financial performance is no guarantee of future results. ."], "table": [["net tangible assets acquired as of september 18 2007", "$ 2800"], ["developed technology and know how", "12300"], ["customer relationship", "17000"], ["trade name", "2800"], ["deferred income tax liabilities net", "-9500 ( 9500 )"], ["goodwill", "47800"], ["final purchase price", "$ 73200"]], "table_ori": [["Net tangible assets acquired as of September 18, 2007", "$2,800"], ["Developed technology and know how", "12,300"], ["Customer relationship", "17,000"], ["Trade name", "2,800"], ["Deferred income tax liabilities, net", "(9,500)"], ["Goodwill", "47,800"], ["Final purchase price", "$73,200"]]}

Question: what portion of the final purchase price is related to developed technology?
Evidence:
table_1: net tangible assets acquired as of september 18 2007 the developed technology and know how of $ 2800 is 12300 ;
table_6: net tangible assets acquired as of september 18 2007 the final purchase price of $ 2800 is $ 73200 ;
Program: divide(12300, 73200)
Answer:
str_answer: 16.8%
exe_answer: 0.16803